<DOC>
	<DOC>NCT01432730</DOC>
	<brief_summary>This is a randomised, double-blind, placebo-controlled, crossover, single centre study of AF-219 in subjects with idiopathic chronic cough designed to evaluate the effectiveness of AF-219 in reducing daytime objective cough frequency.</brief_summary>
	<brief_title>A Study to Assess the Efficacy of AF-219, a P2X3 Receptor Antagonist, in Subjects With Chronic Cough</brief_title>
	<detailed_description />
	<mesh_term>Cough</mesh_term>
	<criteria>History of cough for more than 8 weeks Normal chest radiograph Idiopathic or treatment resistant cough (idiopathic defined as a cough for which no objective evidence of an underlying trigger can be determined after investigation or a cough that is unresponsive to 8 weeks of targeted treatment for identified underlying triggers including reflux disease, asthma and postnasal drip [treatmentresistant]). Current smoker Individuals who have given up smoking within the past 6 months, or those with &gt;20 packyear smoking history Treatment with an ACEinhibitor as the potential cause of a subject's cough, or requiring treatment with an ACEinhibitor during the study or within 4 weeks prior to Day 0 FEV1/FVC &lt;60%</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>